Header Logo

Connection

William Towner to Adult

Back to Details
This is a "connection" page, showing publications William Towner has written about Adult.
William Towner
Connection Strength
0.828
Adult
  1. Effect of an Electronic Alert on Targeted HIV Testing Among High-Risk Populations. Perm J. 2018; 22:18-015.
    View in: PubMed
    Score: 0.065
  2. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
    View in: PubMed
    Score: 0.044
  3. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):614-8.
    View in: PubMed
    Score: 0.038
  4. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther. 2010; 15(6):803-16.
    View in: PubMed
    Score: 0.037
  5. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):367-73.
    View in: PubMed
    Score: 0.036
  6. Trends and correlates of HIV testing during pregnancy in racially/ethnically diverse insured population, 1997-2006. Matern Child Health J. 2009 Sep; 13(5):633-40.
    View in: PubMed
    Score: 0.034
  7. Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems. J Acquir Immune Defic Syndr. 2023 12 01; 94(4):341-348.
    View in: PubMed
    Score: 0.025
  8. Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine. Vaccine. 2023 Jul 05; 41(30):4392-4401.
    View in: PubMed
    Score: 0.024
  9. Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction. JAMA. 2022 04 05; 327(13):1260-1268.
    View in: PubMed
    Score: 0.022
  10. Association of Number of Doses With Hepatitis B Vaccine Series Completion in US Adults. JAMA Netw Open. 2020 11 02; 3(11):e2027577.
    View in: PubMed
    Score: 0.020
  11. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Netw Open. 2020 06 01; 3(6):e207954.
    View in: PubMed
    Score: 0.019
  12. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.
    View in: PubMed
    Score: 0.019
  13. Effect of Physical Activity Coaching on Acute Care and Survival Among Patients With Chronic Obstructive Pulmonary Disease: A Pragmatic Randomized Clinical Trial. JAMA Netw Open. 2019 08 02; 2(8):e199657.
    View in: PubMed
    Score: 0.018
  14. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017 05; 18(3):118-125.
    View in: PubMed
    Score: 0.016
  15. Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. AIDS. 2017 04 24; 31(7):989-993.
    View in: PubMed
    Score: 0.016
  16. Examining HIV Viral Load in a Matched Cohort of HIV Positive Individuals With and Without Psoriasis. J Drugs Dermatol. 2017 Apr 01; 16(4):372-377.
    View in: PubMed
    Score: 0.015
  17. Invasive Pneumococcal Disease Among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System. AIDS Patient Care STDS. 2016 10; 30(10):463-470.
    View in: PubMed
    Score: 0.015
  18. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):413-9.
    View in: PubMed
    Score: 0.014
  19. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
    View in: PubMed
    Score: 0.014
  20. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31; 373(27):2599-607.
    View in: PubMed
    Score: 0.014
  21. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):818-26.
    View in: PubMed
    Score: 0.014
  22. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):809-17.
    View in: PubMed
    Score: 0.014
  23. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
    View in: PubMed
    Score: 0.014
  24. Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care STDS. 2015 Jul; 29(7):370-8.
    View in: PubMed
    Score: 0.014
  25. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1167-73.
    View in: PubMed
    Score: 0.013
  26. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015 Apr 15; 60(8):1278-80.
    View in: PubMed
    Score: 0.013
  27. HIV infection and incidence of ischemic stroke. AIDS. 2014 Aug 24; 28(13):1911-9.
    View in: PubMed
    Score: 0.013
  28. Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. 2014 Aug 15; 66(5):495-502.
    View in: PubMed
    Score: 0.013
  29. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 01; 384(9954):1597-605.
    View in: PubMed
    Score: 0.013
  30. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014 Apr 24; 28(7):989-97.
    View in: PubMed
    Score: 0.013
  31. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials. 2014 Mar-Apr; 15(2):51-6.
    View in: PubMed
    Score: 0.012
  32. Hepatitis B testing and vaccination among adults with sexually transmitted infections in a large managed care organization. Clin Infect Dis. 2014 Jun; 58(12):1739-45.
    View in: PubMed
    Score: 0.012
  33. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
    View in: PubMed
    Score: 0.012
  34. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
    View in: PubMed
    Score: 0.011
  35. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012 Jun 01; 60(2):183-90.
    View in: PubMed
    Score: 0.011
  36. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1630-6.
    View in: PubMed
    Score: 0.011
  37. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
    View in: PubMed
    Score: 0.011
  38. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011 Sep 10; 25(14):1771-7.
    View in: PubMed
    Score: 0.011
  39. Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California. AIDS Patient Care STDS. 2011 Sep; 25(9):525-32.
    View in: PubMed
    Score: 0.010
  40. HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. 2011 Jan; 25(1):21-8.
    View in: PubMed
    Score: 0.010
  41. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
    View in: PubMed
    Score: 0.010
  42. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
    View in: PubMed
    Score: 0.009
  43. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010; 15(7):1045-52.
    View in: PubMed
    Score: 0.009
  44. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13; 23(17):2337-45.
    View in: PubMed
    Score: 0.009
  45. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
    View in: PubMed
    Score: 0.009
  46. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. HIV Clin Trials. 2008 May-Jun; 9(3):152-63.
    View in: PubMed
    Score: 0.008
  47. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
    View in: PubMed
    Score: 0.008
  48. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.
    View in: PubMed
    Score: 0.008
  49. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS. 2003 Jun; 17(6):267-75.
    View in: PubMed
    Score: 0.006

© 2024 Kaiser Permanente